Press Release Summary:
- Offers sterile, closed, single-use kits that enables cell processing in grade C clean rooms
- Provides processing flexibility to support broad range of protocols for cell separation, washing and concentration
- Facilitates workflows from research through GMP clinical development and commercial manufacturing
Original Press Release:
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
CARLSBAD, Calif., Oct. 15, 2020 /PRNewswire/ -- Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and facilitates workflows from research through GMP clinical development and commercial manufacturing.
As of mid-2020, 675 clinical trials were underway globally for cell therapy and cell-based immune-oncology, according to the Alliance for Regenerative Medicine. Yet few cell therapies in development become commercially available due to several factors: safety and efficacy requirements, difficulties in transferring research protocols to manufacturing processes, lack of scalability of these therapies, high cost of facilities, labor and equipment, and complexity of the processes involved.
Using a modular, closed system for cell processing enables time-consuming processes to be decoupled from rapid processes, improving facility and equipment utilization and reducing the capital investment required. Use of the same system from research through process development and commercial manufacturing lowers the risk of process delays associated with changing systems. Sterile, closed, single-use kits enable cell processing in grade C clean rooms, leading to cost-effective transfer and scale-out of processes.
"It is notoriously difficult for cell therapies to advance from the research stage into the marketplace," said Amy Butler, president of the biosciences business at Thermo Fisher Scientific. "Our goal is to help advance the development of cell therapies, including exciting new CAR T cell therapies and even potential cell therapies to repair lung damage caused by COVID-19. The CTS Rotea system will help researchers overcome manufacturing hurdles and bring the vast potential of cell therapies to more patients."
The multifunctional and highly flexible CTS Rotea system can easily integrate into existing workflows, process low- to mid-range input volumes, and deliver low output volumes. Consisting of an instrument, closed sterile single use kit, and user programmable software, the CTS Rotea system provides processing flexibility to support a broad range of protocols for cell separation, washing and concentration with a cell recovery yield of greater than 95 percent while maintaining cell viability.
For more information on the CTS Rotea Counterflow Centrifugation System, visit the company website.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
Media Contact Information: